TETRAULT LYNN A. 4

What Happened Lynn A. Tetrault, a director of Neogenomics, reported the sale of 5,307 shares of Neogenomics common stock on June 15, 2026. The shares were sold in an open-market/private sale at $11.10 per share for a total sale value of $58,908. This was a sale (not a purchase) and is typically considered a routine insider disposition rather than an affirmative bullish purchase.

Key Details

• Transaction date: June 15, 2026
• Transaction type: Open market/private sale (Code S)
• Price per share: $11.10; Shares sold: 5,307; Total proceeds: $58,908
• Shares owned after transaction: Not specified in the provided filing details
• Footnote: F1 — once vested, the shares of common stock are not subject to expiration
• Filing: Form 4 filed June 17, 2026 (filed within the standard two-business-day reporting window)

Context Sales by directors can be for many personal or portfolio reasons and do not by themselves indicate a change in company prospects. The filing’s footnote notes these were vested shares that aren't subject to expiration; no indication was given of an option exercise, 10b5-1 plan, or gift in the provided details.